GSA CAPITAL PARTNERS LLP - AXOVANT GENE THERAPIES LTD ownership

AXOVANT GENE THERAPIES LTD's ticker is AXGT and the CUSIP is G0750W203. A total of 51 filers reported holding AXOVANT GENE THERAPIES LTD in Q3 2020. The put-call ratio across all filers is 1.58 and the average weighting 0.1%.

Quarter-by-quarter ownership
GSA CAPITAL PARTNERS LLP ownership history of AXOVANT GENE THERAPIES LTD
ValueSharesWeighting
Q3 2020$559,000
+270.2%
120,925
+126.5%
0.09%
+10.7%
Q2 2020$151,000
+51.0%
53,384
+30.1%
0.08%
+236.0%
Q1 2020$100,000
-51.7%
41,037
+1.7%
0.02%
+4.2%
Q4 2019$207,000
+149.4%
40,343
+213.7%
0.02%
+118.2%
Q3 2019$83,000
-47.8%
12,861
-49.7%
0.01%
-38.9%
Q2 2019$159,00025,5610.02%
Other shareholders
AXOVANT GENE THERAPIES LTD shareholders Q3 2020
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,021,566$2,493,0001.04%
SPHERA FUNDS MANAGEMENT LTD. 2,931,018$7,152,0000.90%
Consonance Capital Management LP 3,653,303$8,914,0000.66%
Rubric Capital Management LP 460,200$1,123,0000.18%
Hudson Bay Capital Management LP 1,350,000$3,294,0000.08%
Ikarian Capital, LLC 188,884$461,0000.04%
GSA CAPITAL PARTNERS LLP 41,037$100,0000.02%
Spark Investment Management LLC 18,072$44,0000.02%
Cable Hill Partners, LLC 15,000$37,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 38,800$95,0000.01%
View complete list of AXOVANT GENE THERAPIES LTD shareholders